In a report published by Deutsche Bank, analyst Darren Lehrich upgraded DaVita DVA from Hold to Buy and raised the price target from $130 to $136.
In the report, Deutsche Bank noted, "When we downgraded DVA shares last month, our primary concern was the potential for a much more challenging 2014 outlook due to CMS' approach to Medicare Advantage (MA) rates in its February 15th proposal. Given the final outcome from CMS' MA regulation (with MA rates ~500 bps better vs. proposed), we are now less concerned about HCP's yoy earnings trajectory. This gives us greater confidence that DVA can stay on a pathway to earn well north of $9/share in cash EPS."
Shares of DaVita closed at $119.91 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in